Shots: The approval is based on P-III ‘1053’ trial conducted across 34 sites in 14 countries assessing Lumoxiti (moxetumomab pasudotox-tdfk) in patients with r/r HCL, testing its safety, efficacy, immunogenicity and PK P-III ‘1053’ trial (N=80) results: ORR (75%); DOR (30%); CR (41%); PRR (34%); hematologic remission rate (80%) Lumoxiti (CD22-directed cytotoxin) novel treatment in […]Read More
